Angiography

1
Pipeline Programs
1
Companies
8
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Bayer
ULTRAVIST 370Approved
iopromide
Bayer
Radiographic Contrast Agent [EPC]injection1995

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
ULTRAVIST 370(Iopromide)N/A5 trials
Active Trials
NCT05428397Completed152,233Est. Oct 2022
NCT04605471Completed132,850Est. Mar 2021
NCT03622801Completed133,331Est. Feb 2019
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerIopromide
BayerIopromide
BayerIopromide
BayerIopromide
BayerIopromide
BayerIopromide
BayerIopromide
BayerIopromide

Clinical Trials (8)

Total enrollment: 494,156 patients across 8 trials

Ultravist: Safety and Efficacy in Computed Tomography of Head and Body

Start: Oct 2005Est. completion: Apr 2008435 patients
Phase 3Completed

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Start: Jun 2022Est. completion: Oct 2022152,233 patients
N/ACompleted

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Start: Oct 2020Est. completion: Mar 2021132,850 patients
N/ACompleted

Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid

Start: Oct 2018Est. completion: Feb 2019133,331 patients
N/ACompleted

A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting

Start: Jul 2016Est. completion: Oct 20171,214 patients
N/ACompleted

Observational Study of Ultravist in Patients Requiring CECT

Start: Sep 2011Est. completion: Nov 201311,660 patients
N/ACompleted

The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)

Start: Aug 2010Est. completion: Sep 201117,513 patients
N/ACompleted

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

Start: Mar 2008Est. completion: Sep 200944,920 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space